CA3033239A1 - Inhibiteurs spiro bicycliques de l'interaction menine-mll - Google Patents

Inhibiteurs spiro bicycliques de l'interaction menine-mll Download PDF

Info

Publication number
CA3033239A1
CA3033239A1 CA3033239A CA3033239A CA3033239A1 CA 3033239 A1 CA3033239 A1 CA 3033239A1 CA 3033239 A CA3033239 A CA 3033239A CA 3033239 A CA3033239 A CA 3033239A CA 3033239 A1 CA3033239 A1 CA 3033239A1
Authority
CA
Canada
Prior art keywords
group
optionally substituted
4alkyl
hydrogen
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3033239A
Other languages
English (en)
Inventor
Patrick Rene Angibaud
Vineet PANDE
Barbara HERKERT
Daniel Jason Krosky
Olivier Alexis Georges Querolle
Isabelle Noelle Constance Pilatte
Aaron Nathaniel PATRICK
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of CA3033239A1 publication Critical patent/CA3033239A1/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des agents pharmaceutiques utiles pour la thérapie et/ou la prophylaxie chez un mammifère, et en particulier des composés spiro bicycliques, une composition pharmaceutique comprenant de tels composés, et leur utilisation en tant qu'inhibiteurs d'interactions ménine/protéine MLL/protéine, utiles pour le traitement de maladies telles que le cancer, le syndrome myélodysplasique (MDS) et le diabète.
CA3033239A 2016-09-14 2017-09-13 Inhibiteurs spiro bicycliques de l'interaction menine-mll Pending CA3033239A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662394295P 2016-09-14 2016-09-14
US62/394,295 2016-09-14
EP16192431 2016-10-05
EP16192431.1 2016-10-05
PCT/EP2017/073004 WO2018050686A1 (fr) 2016-09-14 2017-09-13 Inhibiteurs spiro bicycliques de l'interaction ménine-mll

Publications (1)

Publication Number Publication Date
CA3033239A1 true CA3033239A1 (fr) 2018-03-22

Family

ID=57083210

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3033239A Pending CA3033239A1 (fr) 2016-09-14 2017-09-13 Inhibiteurs spiro bicycliques de l'interaction menine-mll

Country Status (4)

Country Link
CA (1) CA3033239A1 (fr)
EA (1) EA201990699A1 (fr)
TW (1) TWI738864B (fr)
WO (1) WO2018050686A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112771055A (zh) * 2018-08-08 2021-05-07 大日本住友制药株式会社 光学活性桥接哌啶衍生物

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016040330A1 (fr) 2014-09-09 2016-03-17 The Regents Of The University Of Michigan Composés de thiénopyrimidine et de thiénopyridine et leurs procédés d'utilisation
AR104020A1 (es) 2015-06-04 2017-06-21 Kura Oncology Inc Métodos y composiciones para inhibir la interacción de menina con proteínas mill
WO2016197027A1 (fr) 2015-06-04 2016-12-08 Kura Oncology, Inc. Méthodes et compositions d'inhibition de l'interaction de la ménine avec les protéines mll
CN109640987B (zh) 2016-03-16 2022-12-02 库拉肿瘤学公司 Menin-mll的桥联双环抑制剂及使用方法
CN109152784B (zh) 2016-03-16 2021-12-28 库拉肿瘤学公司 经取代的menin-mll抑制剂及使用方法
MA46228A (fr) 2016-09-14 2019-07-24 Janssen Pharmaceutica Nv Inhibiteurs bicycliques fusionnés de l'interaction ménine-mll
US12084462B2 (en) 2016-09-14 2024-09-10 Janssen Pharmaceutica Nv Spiro bicyclic inhibitors of menin-MLL interaction
CN109689663B (zh) 2016-09-14 2023-04-14 詹森药业有限公司 Menin-mll相互作用的螺二环抑制剂
BR112019012106A2 (pt) 2016-12-15 2019-10-29 Janssen Pharmaceutica Nv inibidores de azepano de interação menin-mill
CN110691779B (zh) 2017-03-24 2023-10-10 库拉肿瘤学公司 治疗血液系统恶性肿瘤和尤因肉瘤的方法
US11542248B2 (en) 2017-06-08 2023-01-03 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with MLL proteins
US11649251B2 (en) 2017-09-20 2023-05-16 Kura Oncology, Inc. Substituted inhibitors of menin-MLL and methods of use
KR20200101389A (ko) * 2017-12-20 2020-08-27 얀센 파마슈티카 엔.브이. 메닌-mll 상호작용의 엑소-아자 스피로 억제제
US11396517B1 (en) 2017-12-20 2022-07-26 Janssen Pharmaceutica Nv Exo-aza spiro inhibitors of menin-MLL interaction
US11325921B2 (en) 2018-03-30 2022-05-10 Sumitomo Dainippon Pharma Co., Ltd. Optically active crosslinked cyclic secondary amine derivative
SG11202101085PA (en) * 2018-08-27 2021-03-30 Sumitomo Dainippon Pharma Co Ltd Optically active azabicyclic derivative
US10815241B2 (en) 2018-08-27 2020-10-27 Sumitomo Dainippon Pharma Co., Ltd. Optically active azabicyclo ring derivative
AU2019395201A1 (en) 2018-12-06 2021-05-20 Daiichi Sankyo Company, Limited Cycloalkane-1,3-diamine derivative
WO2021060453A1 (fr) * 2019-09-27 2021-04-01 大日本住友製薬株式会社 Dérivé d'amine secondaire optiquement actif réticulé
JP7554829B2 (ja) 2019-12-19 2024-09-20 ヤンセン ファーマシューティカ エヌ．ベー． 置換直鎖スピロ誘導体
EP4334320A1 (fr) 2021-05-08 2024-03-13 JANSSEN Pharmaceutica NV Dérivés spiro substitués
MX2023013174A (es) 2021-05-08 2023-11-30 Janssen Pharmaceutica Nv Derivados espiro sustituidos.
WO2022253167A1 (fr) 2021-06-01 2022-12-08 Janssen Pharmaceutica Nv Dérivés de phényl-1h-pyrrolo [2, 3-c] pyridine substitués
CN117425659A (zh) 2021-06-03 2024-01-19 詹森药业有限公司 哒嗪或被螺环胺取代的1,2,4-三嗪
CA3220099A1 (fr) 2021-06-17 2022-12-22 Wei Cai Sel de besylate (r)-n-ethyl-5-fluoro-n-isopropyl-2-((5-(2-(6-((2-methoxyethyl)(methyl)amino)-2-m ethylhexan-3-yl)-2,6-diazaspiro[3.4]octan-6-yl)-1,2,4-triazin-6-yl)oxy)benzamide pour le traitement de maladies telles que le cance
CN120379996A (zh) * 2022-08-11 2025-07-25 瑞敏德股份有限公司 用于治疗神经退行性障碍的(氮杂)螺庚烷衍生物
CN120529900A (zh) 2022-11-24 2025-08-22 奥莱松基因组股份有限公司 用于治疗癌症的LSD1抑制剂和Menin抑制剂的组合

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2473054B1 (fr) 2009-09-04 2017-06-14 The Regents of the University of Michigan Compositions et méthodes de traitement de la leucémie
KR20150130389A (ko) * 2013-03-13 2015-11-23 더 리젠츠 오브 더 유니버시티 오브 미시간 티에노피리미딘 및 티에노피리딘 화합물을 포함하는 조성물 및 이의 사용 방법
CN105732636B (zh) * 2014-12-30 2020-04-21 广东东阳光药业有限公司 杂芳化合物及其在药物中的应用
AU2016378579A1 (en) 2015-12-22 2018-06-14 Vitae Pharmaceuticals, Inc. Inhibitors of the menin-MLL interaction

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112771055A (zh) * 2018-08-08 2021-05-07 大日本住友制药株式会社 光学活性桥接哌啶衍生物
CN112771055B (zh) * 2018-08-08 2023-10-20 住友制药株式会社 光学活性桥接哌啶衍生物

Also Published As

Publication number Publication date
TW201823250A (zh) 2018-07-01
TWI738864B (zh) 2021-09-11
WO2018050686A1 (fr) 2018-03-22
EA201990699A1 (ru) 2019-09-30

Similar Documents

Publication Publication Date Title
CA3033239A1 (fr) Inhibiteurs spiro bicycliques de l'interaction menine-mll
EP3512857B1 (fr) Inhibiteurs spiro-bicyclique de menin-mll-interaction
CN109715634B (zh) Menin-mll相互作用的稠合二环抑制剂
EP3145929B1 (fr) Composés 5-chloro -2-difluorométhoxyphényl pyrazolopyrimidine utilisés en tant qu'inhibiteurs de jak
WO2018109088A1 (fr) Inhibiteurs d'azépane de l'interaction ménine-mll
US11530226B2 (en) Azepane inhibitors of menin-MLL interaction
US12084462B2 (en) Spiro bicyclic inhibitors of menin-MLL interaction
EA045364B1 (ru) Спиробициклические ингибиторы взаимодействия менин-mll
HK40008247A (en) Fused bicyclic inhibitors of menin-mll interaction
HK40007797A (zh) Menin-mll相互作用的螺二环抑制剂
HK40015432A (en) Azepane inhibitors of menin-mll interaction
HK40015432B (en) Azepane inhibitors of menin-mll interaction
EA045404B1 (ru) Конденсированные бициклические ингибиторы взаимодействия менин-mll
OA16957A (en) PDE9 inhibitors with imidazo triazinone backbone.

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220906

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D120 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: VOLUNTARY SUBMISSION OF PRIOR ART RECEIVED

Effective date: 20240917

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241218

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D123 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIOR ART DISCLOSURE DETERMINED COMPLIANT

Effective date: 20250212

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250212

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250604

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250729

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250729

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-T10-T11-T100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXTENSION OF TIME FOR TAKING ACTION REQUEST RECEIVED

Effective date: 20251001

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20251208

T13 Administrative time limit extension granted

Free format text: ST27 STATUS EVENT CODE: A-2-2-T10-T13-T101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXTENSION OF TIME FOR TAKING ACTION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20251211

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20251211